Prohibiting Generic Drug Delays: Lower Prices, More Choices
This act aims to lower drug prices and increase their availability by prohibiting brand-name drug manufacturers from paying generic drug manufacturers to delay their market entry. Citizens can expect faster access to more affordable alternatives, positively impacting their personal finances and access to essential treatments. The Federal Trade Commission will enforce these provisions, imposing significant penalties for violations.
Key points
Prohibits payments to delay the market entry of generic and biosimilar drugs, aiming to accelerate their availability.
Potential for lower drug prices for consumers due to increased competition.
The Federal Trade Commission (FTC) gains new powers to impose financial penalties and take legal action against companies violating these rules.
Companies must report all agreements related to patent disputes, and their executives must certify their completeness and legality.
Expired
Citizen Poll